Rédaction Africa Links 24 with Meghana Keshavan
Published on 2024-02-23 14:06:44
Biotechnology is a rapidly evolving field that is driven by both science and politics. Staying informed about the latest developments and news in biotech is crucial for professionals and enthusiasts alike. If you want to stay on top of the science and politics driving biotech today, signing up for a biotech newsletter can be a great way to receive relevant information directly in your inbox.
In today’s discussion, we focus on the FDA’s firm stance on handling non-compliant trial sponsors and investigators, PhRMA’s efforts to rebuild its membership, and a notable biotech podcast worth checking out.
In the latest episode of “The Readout LOUD,” a biotech podcast by STAT, former Alnylam Pharmaceuticals CEO John Maraganore and STAT’s Matthew Herper discuss the legacy of AbbVie chief executive Richard Gonzalez, who recently announced his retirement. The podcast also delves into the intriguing world of fetal genome surgery, with STAT’s Megan Molteni sharing insights into the work of scientist Tippi MacKenzie. If you’re interested, you can listen to the podcast to learn more about these topics.
Annovis Bio made headlines with a controversial decision to change the endpoint of a Phase 3 Parkinson’s trial at the last minute. CEO Maria Maccecchini explained that the FDA suggested a more appropriate primary outcome measure, leading to the late change in trial design. While the company’s transparency is commendable, some may view the situation as a “Hail Mary” approach, raising questions about the likelihood of positive results.
The FDA’s approach to trial transparency is also under scrutiny, as they are hoping for voluntary compliance from trial sponsors and investigators to register trials and report study results. While the agency won’t be imposing fines or sanctions, they will maintain a dashboard tracking notices sent to non-compliant entities. This comes in response to a petition filed by the Universities Allied for Essential Medicines, advocating for stronger trial transparency measures.
In industry news, Neurocrine Biosciences recently joined PhRMA, a drug lobbying group, following the departure of some high-profile members due to drug pricing legislation. With substantial lobbying efforts despite its size, Neurocrine’s membership adds to PhRMA’s influence. This addition follows Genmab joining the trade group in December, signaling continued growth and diversity within PhRMA.
Other notable reads in the biotech space include the potential economic impact of weight loss drugs on the US GDP, AbbVie’s oncology and immunology deal with Tentarix, and Indivior’s plans to shift its primary listing from London to New York.
For those who have made it this far, consider joining a secret list for an upcoming biotech newsletter to continue receiving valuable insights and updates in the industry. Keeping abreast of the latest developments in biotechnology is crucial for staying informed and making informed decisions in this rapidly evolving field.
